- call +1-201-465-4211
- email sales@mrinsights.biz
Gigantism refers to abnormally high linear growth due to excessive action of insulinlike growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the growth plate cartilage fuses in adulthood.
Scope of the Report:
This report focuses on the Acromegaly and Gigantism Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The global acromegaly and gigantism treatment market can be segmented into treatment, end users, and geographical expansion. On the basis of treatment, the market is divided into surgery, radiation therapy, and medication. The medication segment can be further divided into different drug types such as somatostatin analogs, GH receptor antagonists, dopamine agonists and others. The medication segment is expected to hold a significant market share during the forecast period due to factors such as effectiveness of drugs, noninvasive and lesser side effects than radiation therapies, and strong pipeline portfolio.
The worldwide market for Acromegaly and Gigantism Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Ipsen
Novartis
Pfizer
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Somatostatin Analogs
GH Receptor Antagonists
Dopamine Agonists
Recombinant Human IGF-1
Market Segment by Applications, can be divided into
Hospitals
Clinics
Others
There are 15 Chapters to deeply display the global Acromegaly and Gigantism Drugs market.
Chapter 1, to describe Acromegaly and Gigantism Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Acromegaly and Gigantism Drugs, with sales, revenue, and price of Acromegaly and Gigantism Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Acromegaly and Gigantism Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Acromegaly and Gigantism Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Acromegaly and Gigantism Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Acromegaly and Gigantism Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Somatostatin Analogs
1.2.2 GH Receptor Antagonists
1.2.3 Dopamine Agonists
1.2.4 Recombinant Human IGF-1
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Ipsen
2.1.1 Business Overview
2.1.2 Acromegaly and Gigantism Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Ipsen Acromegaly and Gigantism Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis
2.2.1 Business Overview
2.2.2 Acromegaly and Gigantism Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis Acromegaly and Gigantism Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Pfizer
2.3.1 Business Overview
2.3.2 Acromegaly and Gigantism Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Pfizer Acromegaly and Gigantism Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Acromegaly and Gigantism Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Acromegaly and Gigantism Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Acromegaly and Gigantism Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Acromegaly and Gigantism Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Acromegaly and Gigantism Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Acromegaly and Gigantism Drugs Market Analysis by Regions
4.1 Global Acromegaly and Gigantism Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Acromegaly and Gigantism Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Acromegaly and Gigantism Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
4.5 South America Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
5 North America Acromegaly and Gigantism Drugs by Countries
5.1 North America Acromegaly and Gigantism Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Acromegaly and Gigantism Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Acromegaly and Gigantism Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
6 Europe Acromegaly and Gigantism Drugs by Countries
6.1 Europe Acromegaly and Gigantism Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Acromegaly and Gigantism Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Acromegaly and Gigantism Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
6.3 UK Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
6.4 France Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Acromegaly and Gigantism Drugs by Countries
7.1 Asia-Pacific Acromegaly and Gigantism Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Acromegaly and Gigantism Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Acromegaly and Gigantism Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
7.5 India Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
8 South America Acromegaly and Gigantism Drugs by Countries
8.1 South America Acromegaly and Gigantism Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Acromegaly and Gigantism Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Acromegaly and Gigantism Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Acromegaly and Gigantism Drugs by Countries
9.1 Middle East and Africa Acromegaly and Gigantism Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Acromegaly and Gigantism Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Acromegaly and Gigantism Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Acromegaly and Gigantism Drugs Sales and Growth Rate (2013-2018)
10 Global Acromegaly and Gigantism Drugs Market Segment by Type
10.1 Global Acromegaly and Gigantism Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Acromegaly and Gigantism Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Acromegaly and Gigantism Drugs Revenue and Market Share by Type (2013-2018)
10.2 Somatostatin Analogs Sales Growth and Price
10.2.1 Global Somatostatin Analogs Sales Growth (2013-2018)
10.2.2 Global Somatostatin Analogs Price (2013-2018)
10.3 GH Receptor Antagonists Sales Growth and Price
10.3.1 Global GH Receptor Antagonists Sales Growth (2013-2018)
10.3.2 Global GH Receptor Antagonists Price (2013-2018)
10.4 Dopamine Agonists Sales Growth and Price
10.4.1 Global Dopamine Agonists Sales Growth (2013-2018)
10.4.2 Global Dopamine Agonists Price (2013-2018)
10.5 Recombinant Human IGF-1 Sales Growth and Price
10.5.1 Global Recombinant Human IGF-1 Sales Growth (2013-2018)
10.5.2 Global Recombinant Human IGF-1 Price (2013-2018)
11 Global Acromegaly and Gigantism Drugs Market Segment by Application
11.1 Global Acromegaly and Gigantism Drugs Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Clinics Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Acromegaly and Gigantism Drugs Market Forecast (2018-2023)
12.1 Global Acromegaly and Gigantism Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Acromegaly and Gigantism Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Acromegaly and Gigantism Drugs Market Forecast (2018-2023)
12.2.2 Europe Acromegaly and Gigantism Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Acromegaly and Gigantism Drugs Market Forecast (2018-2023)
12.2.4 South America Acromegaly and Gigantism Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Acromegaly and Gigantism Drugs Market Forecast (2018-2023)
12.3 Acromegaly and Gigantism Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Acromegaly and Gigantism Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Acromegaly and Gigantism Drugs Market Share Forecast by Type (2018-2023)
12.4 Acromegaly and Gigantism Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Acromegaly and Gigantism Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Acromegaly and Gigantism Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Acromegaly and Gigantism Drugs Picture
Table Product Specifications of Acromegaly and Gigantism Drugs
Figure Global Sales Market Share of Acromegaly and Gigantism Dr
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
